Livostin

Active Ingredient(s): Levocabastine
FDA Approved: * November 10, 1993
Pharm Company: * NOVARTIS
Category: Allergies, Cough & Cold

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Livostin Overview

Levocabastine (trade name Livostin) is a selective second-generation H1 receptor antagonist which was discovered at Janssen Pharmaceutica in 1979. It is used for allergic conjunctivitis.[2] As well as acting as an antihistamine, levocabastine has also subsequently been found to act as a potent and selective antagonist for the neurotensin receptor NTS2, and was the first drug used to characterise the different neurotensin subtypes.[3][4] This has...

Read more Livostin Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Levocabastine

Recent Livostin Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Levocabastine
  • Suspension: 0.05%
  • Suspension/drops: 0.05%
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Levocabastine or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 15 October 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA